Sparfloxacin pharmacokinetics in healthy volunteers: The influence of acidification and alkalinization

European Journal of Clinical Pharmacology

Volumn 54, Issue 8, 1998, Pages 633-637

  Kamberi, M ^a   Kotegawa, T ^a   Tsutsumi, K ^a   Nakamura, K ^a   Nakano, S ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Sparfloxacin

Indexed keywords

AMMONIUM CHLORIDE; BICARBONATE; SPARFLOXACIN;

ACIDIFICATION; ADULT; ALKALINIZATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; JAPAN; KIDNEY TUBULE ABSORPTION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINE PH;

ADMINISTRATION, ORAL; ADULT; AMMONIUM CHLORIDE; ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FASTING; FLUOROQUINOLONES; HUMANS; MALE; OXIDATION-REDUCTION; QUINOLONES; SODIUM BICARBONATE;

EID: 0031769466     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050526     Document Type: Article

References (25)

1. Cohen MA, Huband MD, Mailloux GB, Yoder SL, Roland GE, Heifetz CL (1991) In vitro activity of sparfloxacin (CI-978, AT4140, and PD-13150): a quinolone with high activity against gram-positive bacteria. Diagn Microbiol Infect Dis 14: 403-415
2. Cooper MA, Andrews JM, Ashby JP, Matthews RS, Wise R (1990) In vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother 26: 667-676
3. Giamarellou H, Voutsians D, Xirouchaki E (1992) Comparative in vitro activity of sparfloxacin (AT-4140, RP-64206, SPFX) against 275 multiresistant clinical isolates. J Chemother 4: 12-15
4. Fritz S, Ulrich J, Kurt N, Ulrich S (1989) Pharmacokinetic disposition of quinolones in human body fluids and tissues. J Clin Pharmacokinet 16 [Suppl 1]: 5-24
5. Shimada J, Yamaji T, Ueda Y, Uchida H, Kasajima H, Irikura T (1983) Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs and humans. Antimicrob Agents Chemother 23: 1-7
6. Yamaguchi T, Yokogawa M, Sekine Y (1991) Renal excretion mechanism of sparfloxacin. Xenobio Metabol Dispos 6: 61-65
7. Malcolm R, Tozer NT (1993) Elimination In: Malcolm R and Tozer NT (ed) Clinical pharmacokinetics. Concepts and applications, 3rd edn, pp 156-183
8. Yamaguchi T, Yokogawa M, Hashizume T, Baba M, Higuchi Y, Matsuoka N, Sekine Y (1991) Pharmacokinetics of sparfloxacin in rats, dogs and monkeys. Xenobio Metabol Dispos 6: 33-41
9. Prescott FL (1972) Mechanisms of renal excretion of drugs (with special reference to drugs used by anesthetists). Br J Anaesth 44: 246-251
10. Johnston A, Warrington S, Turner P (1485) Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH. Br J Clin Pharmacol 20: 333-338
11. Edwards G, Breckenridge AM, Adjepon-Yamoah KK, Orme ML, Ward SA (1981) The effect of variations in urinary pH on the pharmacokinetics of diethylcarbamazine. Br J Clin Pharmacol 12: 807-812
12. Ulrich J, Fritz S, Ulrich S, Schunack V (1994) Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elemination of perfloxacin in humans. Antimicrob Agents Chemother 38: 1129-1133
13. Nakashima K, Kanamaru M, Uematsu T, Takiguchi Y (1991) Phase I study of pyridone carboxylic acid antibacterial agent, sparfloxacin. Rinsho Iyaku 7: 1639-1684
14. Saito A, Tomizawa M, Nakayama I, Sato K (1991) Basic and clinical studies on sparfloxacin. Chemotherapy (Tokyo) 39 [Suppl 4]: 203-212
15. Sakashita S, Yokogawa M, Yamaguchi T, Sekine Y (1991) Pharmacokinetics of sparfloxacin in man. Xenobio Metabol Dispos 6: 43-51
16. Yamana T, Tsuji A (1976) Comparative stability of cephalosporins in aqueous solutions: kinetics and mechanisms of degradation. J Pharm Sci 65: 1563-1574
17. Prieto JG, Santos L, Barrio JP, Alonso ML (1987) J Pharm Sci 76: 596-600
18. Lee D-S, Han H-J, Kim K, Park W-B, Cho J-K, Kim J-H (1994) Dissociation and complexation of fluoroquinolone analogues. J Pharm Biomed Anal 12: 157-164
19. Fernandes PB (1989) In: International telesymposium on quinolones (ed), Prous Science, Barcelona, pp 21-88
20. Yamaguchi T, Yokogawa M, Sekine Y, Hashimoto M (1991) Intestinal absorption characteristics of sparfloxacin. Xenobio Metabol Dispos 6: 53-59
21. Montay G, Bruno R, Vergniol CJ, Ebmeier M, Le Roux Y, Guimart C, Frydman A, et al (1994) Pharmacokinetics of sparfloxacin in humans after single oral administration of doses 200, 400, 600 and 800 mg. J Clin Pharmacol 34: 1071-1076
22. Johnson R, Geary W, Jenssen B (1996) The absolute oral bioavailability of sparfloxacin in healthy male subjects (abstract). Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans
23. Robson RA (1992) Quinolone pharmacokinetics. Int J Antimicrob Agents 2: 3-10
24. Wolfson JS, Hooper DC (1991) Pharmacokinetics of quinolones: newer aspects. Eur J Clin Microbiol Infect Dis 10: 267-274
25. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ (1995) The importance of pharmacokinetic pharmacodynamic surrogate markers to outcome. Focus on antimicrobial agents. Clin Pharmacokinet 28: 143-160